Key result
r-Hirudin use during PCI warrants reconsideration of its clinical utility.
Key points are not available for this paper at this time.
H. Mehta, B. J. Meyer; r-Hirudin for percutaneous coronary interventions—time to reconsider?, European Heart Journal, Volume 23, Issue 2, 1 January 2002, Pages
No takes yet. Share an insight, caveat, or question.
Haresh Mehta (2002) studied this question. r-Hirudin use during percutaneous coronary interventions warrants reconsideration regarding its clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: